Neurocrine Biosciences (NBIX) Gross Profit (2017 - 2026)

Neurocrine Biosciences' Gross Profit history runs 10 years deep, the most recent figure standing at $800.7 million for Q1 2026.

• Quarterly Gross Profit rose 42.12% year-over-year to $800.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.0 billion (up 28.14% YoY) and the FY2025 annual result came in at $2.8 billion, up 20.98% from the prior year.
• Gross Profit was $800.7 million for Q1 2026 at Neurocrine Biosciences, up from $787.9 million in the prior quarter.
• Across five years, Gross Profit topped out at $800.7 million in Q1 2026 and bottomed at $15.2 million in Q2 2022.
• A 5-year average of $522.7 million and a median of $507.8 million in 2024 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2022 — Gross Profit tumbled 94.68% — and 2023, when it surged 2802.63%.
• Neurocrine Biosciences' Gross Profit stood at $404.3 million in 2022, then climbed by 25.33% to $506.7 million in 2023, then grew by 22.04% to $618.4 million in 2024, then grew by 27.41% to $787.9 million in 2025, then grew by 1.62% to $800.7 million in 2026.
• Business Quant data shows NBIX's Gross Profit at $800.7 million in Q1 2026, $787.9 million in Q4 2025, and $780.9 million in Q3 2025.